Our research team was actively involved in the research and development of transcather aortic valve replacement (TAVR). Moving forward, we continue to improve TAVR systems as we participate in early feasibility trials of transcatheter mitral valve replacement and left ventricular reshaping.

  • Partner 3 Trial

    The purpose of this trial is to establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients with severe, symptomatic aortic stenosis who are at low operative risk for standard aortic valve replacement.

  • SALUS Trial 

    The study is designed to compare the study device (Direct Flow Medical Transcatheter Aortic Valve System) composite event rate to a blended commercial comparator (using approved Medtronic self-expanding bioprosthesis or Edwards balloon-expandable bioprosthesis) in high- and extreme-risk subjects with severe symptomatic aortic stenosis.

  • TAVR Risk Prediction 

    The purpose of this registry is to develop prediction models for clinical outcomes for patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve replacement.

  • COAPT Clinical Trial 

    The purpose of this trial is to confirm the safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe or severe functional mitral regurgitation (FMR) in symptomatic heart failure subjects who are treated per standard of care and who have been determined by the site’s local heart team as not appropriate for mitral valve surgery. We are the third highest enrolling site in the study.

  • Accucinch Ventriculoplasty System 

    This early feasibility trial will assess the safety and performance of the GDS Accucinch System for left ventricular reshaping of the mitral apparatus to reduce mitral regurgitation and improve left ventricular function.

  • CardiAQ Transcatheter Mitral Valve Replacement 

    This early feasibility trial will assess the safety and performance of the Edwards CARDIAC transcatheter-delivered mitral valve.